Federal Policy
340B Program Spending Reached $100 Billion in 2025, Federal Data Shows
Federal data shows 340B drug discount program spending reached $100 billion in 2025, marking continued growth despite regulatory efforts to limit program expansion. The spending increase reflects rising program enrollment and pharmaceutical costs. The growth trajectory affects Medicaid managed care organizations through potential impacts on pharmacy reimbursement rates, contract pharmacy relationships, and state efforts to recoup 340B savings through supplemental rebate programs. Regulators continue efforts to address program growth concerns.
Why it matters340B program expansion affects MCO pharmacy costs, contract pharmacy networks, and state supplemental rebate strategies that directly impact capitation rate adequacy and pharmacy benefit management.